MBIO
Price
$1.25
Change
-$0.03 (-2.34%)
Updated
May 23 closing price
Capitalization
5.47M
ORMP
Price
$2.12
Change
+$0.01 (+0.47%)
Updated
May 23 closing price
Capitalization
86.6M
4 days until earnings call
Interact to see
Advertisement

MBIO vs ORMP

Header iconMBIO vs ORMP Comparison
Open Charts MBIO vs ORMPBanner chart's image
Mustang Bio
Price$1.25
Change-$0.03 (-2.34%)
Volume$96.56K
Capitalization5.47M
Oramed Pharmaceuticals
Price$2.12
Change+$0.01 (+0.47%)
Volume$21.39K
Capitalization86.6M
MBIO vs ORMP Comparison Chart
Loading...
MBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MBIO vs. ORMP commentary
May 24, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBIO is a Hold and ORMP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 24, 2025
Stock price -- (MBIO: $1.25 vs. ORMP: $2.12)
Brand notoriety: MBIO and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MBIO: 19% vs. ORMP: 35%
Market capitalization -- MBIO: $5.47M vs. ORMP: $86.6M
MBIO [@Biotechnology] is valued at $5.47M. ORMP’s [@Biotechnology] market capitalization is $86.6M. The market cap for tickers in the [@Biotechnology] industry ranges from $298.89B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MBIO’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • MBIO’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ORMP is a better buy in the long-term than MBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MBIO’s TA Score shows that 3 TA indicator(s) are bullish while ORMP’s TA Score has 3 bullish TA indicator(s).

  • MBIO’s TA Score: 3 bullish, 5 bearish.
  • ORMP’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both MBIO and ORMP are a bad buy in the short-term.

Price Growth

MBIO (@Biotechnology) experienced а +11.61% price change this week, while ORMP (@Biotechnology) price change was -1.40% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.22%. For the same industry, the average monthly price growth was +3.23%, and the average quarterly price growth was -2.73%.

Reported Earning Dates

MBIO is expected to report earnings on Mar 28, 2025.

ORMP is expected to report earnings on Aug 13, 2025.

Industries' Descriptions

@Biotechnology (+1.22% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORMP($86.6M) has a higher market cap than MBIO($5.47M). ORMP YTD gains are higher at: -12.397 vs. MBIO (-85.876). ORMP has higher annual earnings (EBITDA): 9.44M vs. MBIO (-22.3M). ORMP has more cash in the bank: 142M vs. MBIO (27.5M). ORMP has less debt than MBIO: ORMP (429K) vs MBIO (983K). MBIO (0) and ORMP (0) have equivalent revenues.
MBIOORMPMBIO / ORMP
Capitalization5.47M86.6M6%
EBITDA-22.3M9.44M-236%
Gain YTD-85.876-12.397693%
P/E RatioN/A20.91-
Revenue00-
Total Cash27.5M142M19%
Total Debt983K429K229%
FUNDAMENTALS RATINGS
MBIO vs ORMP: Fundamental Ratings
MBIO
ORMP
OUTLOOK RATING
1..100
151
VALUATION
overvalued / fair valued / undervalued
1..100
91
Overvalued
60
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10079
PRICE GROWTH RATING
1..100
6574
P/E GROWTH RATING
1..100
10046
SEASONALITY SCORE
1..100
9518

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ORMP's Valuation (60) in the Pharmaceuticals Other industry is in the same range as MBIO (91) in the Pharmaceuticals Major industry. This means that ORMP’s stock grew similarly to MBIO’s over the last 12 months.

ORMP's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as MBIO (100) in the Pharmaceuticals Major industry. This means that ORMP’s stock grew similarly to MBIO’s over the last 12 months.

ORMP's SMR Rating (79) in the Pharmaceuticals Other industry is in the same range as MBIO (100) in the Pharmaceuticals Major industry. This means that ORMP’s stock grew similarly to MBIO’s over the last 12 months.

MBIO's Price Growth Rating (65) in the Pharmaceuticals Major industry is in the same range as ORMP (74) in the Pharmaceuticals Other industry. This means that MBIO’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (46) in the Pharmaceuticals Other industry is somewhat better than the same rating for MBIO (100) in the Pharmaceuticals Major industry. This means that ORMP’s stock grew somewhat faster than MBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MBIOORMP
RSI
ODDS (%)
Bullish Trend 2 days ago
89%
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
88%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
84%
Advances
ODDS (%)
Bullish Trend 5 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 12 days ago
90%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
75%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
MBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
HOUS3.340.12
+3.73%
Anywhere Real Estate
BHR2.000.02
+1.01%
Braemar Hotels & Resorts
TXT72.92-0.56
-0.76%
Textron
VCTR61.09-0.59
-0.96%
Victory Capital Holdings
HSDT4.18-0.17
-3.91%
Helius Medical Technologies Inc